Sentinel Lymph Node in Endometrial Cancer. Reem Abdallah, MD American University of Beirut Medical Center

Sentinel Lymph Node in Endometrial Cancer Reem Abdallah, MD American University of Beirut Medical Center

No disclosures

Percent of Cases by Stage

Author Marshall Phillip Morton

7 downloads 518 Views 3MB Size
JOURNAL TRANSCRIPT
Sentinel Lymph Node in Endometrial Cancer Reem Abdallah, MD American University of Beirut Medical Center

No disclosures

Percent of Cases by Stage 8%

Localized (confined to primary site)

4%

21% 67%

Regional (spread to regional LN) Distant (metastatic)

5-year Relative Survival 100 80 60 40 20 0

http://seer.cancer.gov/statfacts/html/corp.html (Accessed on January 31, 2016).

95,3 68,2 48,5 16,9

 LN status: Prognostic value, guide adjuvant trt  Role of Lymphadenectomy controversial  Systematic LND not widely adopted around 30%  Selective, systematic, none.

No LND  65% Low-risk  Pelvic LN mets 9%  ASTEC trial, Panici et al: no therapeutic benefit  Morbidity of comprehensive LND

Selective Risk of nodal mets  size, DOI, grade, LVSI As low as 2% in low risk and Up to 35% in high-risk

Comprehensive  FS variable accuracy  25% with preop grade 1 will be upgraded on final path  Avoid unnecessary adj trt  Therapeutic value? SEPAL study, Chan 2006 SEER

 Risk of nodal mets  size, DOI, grade, LVSI  As low as 2% in low risk and Up to 35% in high-risk  FS variable accuracy  25% with preop grade 1 will be upgraded on final path  Understaging vs overtrt

 Understaging vs overtrt  SLN mid option  Node most likely to harbor mets  SLN endometrial ca first introduced by Burke,1996  Advantages:  avoid unecessary extensive LND of neg LN, associated morbidity,  guide the need of adjuvant trt,  detecting micromets, ultrastaging prognostic significance?

 No RCT re role of SLNB, no long-term survival data

Common Lymphatic Drainage

3% 36% 30%

8%

23%

Classical mapping

Techniques  Radioactive tracer +/- Green or blue dye  Sites of injection:  Cervical (combined superficial (submucosal, 1–3 mm) and deep (stroma, 1–2cm))

 Fundal subserosal  Peritumoral hysteroscopic Courtesy of Abu-Rustum NR, Levine DA, Barakat RR, eds. Atlas of Procedures in Gynecologic Oncology, 3rd ed. London: Informa Healthcare; 2013. c2013, Memorial Sloan-Kettering Cancer Center.

Cervical

Subserosal fundal

Peritumoral

Pros

1. Main lymphatic drainage: parametria 2. Easy, accessible 3. Rarely distorted

1. Better reflection of PA drainage (Detection of PASLN: 39% But Isolated PALN mets in literature 100 cases had detection rate >80%

Cervical

Subserosal fundal

Peritumoral

Pros

1. Main lymphatic drainage: parametria 2. Easy, accessible 3. Rarely distorted

1. Better reflection of PA drainage (Detection of PASLN: 39%)

Cons

1. Low PA detection (Superficial injection: DR 2%, Deep: DR 17%)

1. Not reflective of main lymphatic drainage 2. Rarely infiltrating fundal serosa

1. More complicated 2. Disseminating malignant cells through tubes?

Detection Rates

80-100%

45-75% One study 92%: 8 sites

70-100%

Isolated PALN mets in literature 100 cases had detection rate >80% Most recent studies, DR >92%

Metaanalysis (26 studies, 1101 SLN procedures) Mean SLN detected

2.6 (1-4.7)

Bilaterality of SLN

61% (20%-81%)

Detection Rate

78% (95% CI=73%--84%)

Sensitivity

93% (95% CI=85%–100%)

False Negative Rate

7% (0-14%)

Pericervical injection

Increase in detection rate (p 0.031)

Hysteroscopic only injection Decrease in detection rate (p 0.045) Subserosal only injection

Decrease in sensitivity (p 0.049)

Kang S, Yoo HJ, Hwang JH, et al. Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol 2011;123:522–527

Metaanalysis Studies>30pts SLN procedures

1572

Bilaterality of SLN (Range)

52% (19%-100%)

Detection Rate (Range)

83% (62%-100%)

Sensitivity (Range)

81% (43%-100%)

Algorithm Sensitivity

95% (83%-100%)

Pericervical injection DR

62%-100%

Corporeal injection DR

73%-95%

DR in studies >100 pts

>80%

Cormier et al. Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecol Oncol 2015 Aug;138(2):478-85.

Algorithm Peritoneal and serosal evaluation and washings Retroperitoneal evaluation • Excision of all mapped SLNs with ultrastaging • Any suspicious nodes must be removed regardless of mapping • If no mapping on a hemi-pelvis, side-specific LND • Para-aortic LND at the physician’s discretion Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 2012;125:533

SLN alone

Algorithm

Sensitivity

85.1%

98.1%

Negative Predictive Value

98.1%

99.8%

False Negative Rate

14.9%

1.9%

Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 2012;125:533

Author Barlin Ballester How Niikura Torné Sawicki Vidal Delaloye Solima Lopez-de la Manzanara

N 498 125 100 100 74 70 66 60 59 50

Bats Lopes Holloway Mais Mucke Total

43 40 35 34 31

1385

Algorithm Overall false false Algorithm negative rate negative rate Overall (%) (%) sensitivity (%) sensitivity (%) 13 (7/54) 2 (1/54) 85 98 15 (3/20) 5 (1/20) 84 95 27 (3/11) 9 (1/11) 73 91 17 (3/18) 6 (1/18) 83 94 8 (1/13) 8 (1/13) 92 92 50 (1/2) 0 (0/2) 50 100 57 (4/7) 14 (1/7) 43 86 11 (1/9) 0 (0/9) 89 100 10 (1/10) 0 (0/10) 90 100 0 (0/3) 0 (0/3) 100 100 20 (2/10) 55 (6/11) 10 (1/10) 50 (3/6) 17 (1/6) 19 (37/190)

0 (0/10) 9 (1/11) 10 (1/10) 17 (1/6) 0 (0/6) (9/190)

5

80 45 90 50 83 81

100 91 90 83 100

95

Cormier et al. Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecol Oncol 2015 Aug;138(2):478-85.

Dual Labelling  Standard has been: Isotope+Blue Dye Detection rates: 80-100% Bilateral detection: 40-80%  Combination was not shown to be significantly higher in metaanalysis

Radiolabeled Colloid-Tc99  Short Protocol: 0.2-1 mCi, 2-4 hrs preop  Long Protocol: 2-4 mCi, 20-24 hrs preop  Maximum accumulation in SLN: 1.5hrs  Lymphoscintigram (2 hrs after injection, then every 30 min to detect SLN)  Gamma probes

LSG- Long vs Short Protocol Whole (N=118)

Short (N=44)

Long (n=66)

P

Detection Rate

88 (74.6%)

30 (68.2%)

53 (80.3%)

0.22

Bilateral detection

44 (37.3%)

12 (27.3%)

29 (43.9%)

0.29

0 10 (22.7%)

8 (12.1%) 23 (34.8%)

0.02 0.25

Paraaortic SLN Common iliac SLN Preop LSG

Intraop

Median number of SLN detected per patient

2

1

2

0.02

Number of SLN detected

227

67

146

0.02

Detection Rate

102 (86.4%)

36 (81.8%)

59 (89.4%)

0.62

Bilateral detection

62 (52.5%)

21 (47.4%)

36 (54.5%)

0.89

1 (2.3%) 12 (27.3%)

2 (3%) 16 (24.2%)

1 0.81

92

184

0.5

Paraaortic SLN Common iliac SLN Number of SLN detected

302

Frati et al. Contribution of Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer: Results of the SENTI-ENDO Study. Ann Surg Oncol (2015) 22:1980–1986

LSG

Preop LSG

Intraop

Short (N=44)

Long (n=66)

P

Paraaortic SLN Common iliac SLN

0 10 (22.7%)

8 (12.1%) 23 (34.8%)

0.02 0.25

Number of SLN detected

67

146

0.02

Number of PA SLN detected

0

14 (9.5%)

0.12

6.5%

Number of common SLN iliac detected

18 (27%)

34 (23%)

0.12

31%

Paraaortic SLN Common iliac SLN

1 (2.3%) 12 (27.3%)

2 (3%) 16 (24.2%)

1 0.81

Number of SLN detected

92

184

0.5

Number of PA SLN detected

3 (3.3%)

4 (2.2%)

0.3

Number of common SLN iliac detected

13 (14.1%)

23 (12.5%)

0.55

7%

3%

2.5% 15.5%

Frati et al. Contribution of Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer: Results of the SENTI-ENDO Study. Ann Surg Oncol (2015) 22:1980–1986

Colored Dye  Isosulfan blue 1% (Lymphazurin), Methylene blue 1%, Patent blue 2.5%  Under anesthesia in the OR  2-4 ml  Slowly, 5-10 sec/quadrant  Time to reach LN: 5 min  Median stain time in the SLN: 21 min  Allergic reactions < 5%

Indocyanine Green (ICG)  Near-infrared fluorescence imaging  2-4 ml  Main contraindication: iodine allergy  DR in literature: 85-100%  Bilateral mapping: 65-85%  vs Blue dye:  Higher overall detection rate (87% vs 71%; p = 0.005)  Higher bilateral detection (65% vs 43%; p = 0.002)  In particular, obese

 vs Tc99:  Similar overall (87% vs 88%, p = 0.83) and bilateral (65% vs 71%,p = 0.36) detection

 Combination ICG+Tc99 probably yields the best results

Pathology  H&E  If neg, Ultrastaging:  Two 5 μm sections, at each of two levels 50 μm apart from each paraffin block  H&E and IHC  4 slides/block  +3-7% micromets Kim CH, Soslow RA, Park KJ, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrialcancer staging. Int J Gynecol Cancer 2013;23:968;

Terminology

Definition

Significance

Macromets

tumor clusters >2 mm

Positive

Micromets

tumor clusters 0.2-2 mm

Positive

Isolated tumor cells

single tumor cells or clusters ≤0.2 mm

Positive value and trt still controversial

Isolated cytokeratinpositive “cells” only

Rare isolated cytokeratin-positive cells not identified on corresponding H&Estained sections or do not demonstrate morphologic features of invasive ca

Negative

DMI

Grade 1

Grade 2

Grade 3

Total

No Invasion

MM 1 ITC 1 n = 165

MM 0 ITC 0 n = 39

MM 0 ITC 0 n = 38

2/242 =

< 50% invasion

MM 2 ITC 4 n = 80

MM 0 ITC 4 n = 62

MM 0 ITC 6 n = 56

16/198 = 8.0%

≥ 50% invasion

MM 0 ITC 2 n = 16

MM 0 ITC 0 n = 15

MM 1 ITC 2 n = 37

5/68 = 7.4%

Total

10/261= 3.8%

4/116= 3.4%

9/131 = 6.9%

0.8%

23/508 =

4.5%

Maybe omit ultrastaging if no myometrial invasion

Kim CH, Soslow RA, Park KJ, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrialcancer staging. Int J Gynecol Cancer 2013;23:968;

No MI

DMI

Smile Life

Show life that you have a thousand reasons to smile

Get in touch

© Copyright 2024 ELIB.TIPS - All rights reserved.